Assessment of Therapeutic Efficacy of Mesenchymal Stem Cells in Doxorubicin- Induced Skeletal Myopathy: A histological and Immunological Experimental Study | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Volume 29, Issue 4, October 2020, Page 35-44 PDF (1.2 MB) | ||||
| Document Type: New and original researches in the field of Microbiology. | ||||
| DOI: DOI:https://doi.org/10.51429/EJMM29405 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Ahmed H. Bayoumi1; Ahmed El Zainy2; Amul M. Badr3; Dina Fawzy4; Amal A. Elshimy* 5 | ||||
| 1Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
| 2Department of Anatomy and Histology, College of Medicine, Qassim University, Qassim, Saudi Arabia and Department of Anatomy and Embryology, College of Medicine, Cairo University, Cairo, Egypt | ||||
| 3Department of Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
| 4Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
| 5Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, New Giza University, Cairo, Egypt | ||||
| Abstract | ||||
| Background: Doxorubicin is an effective chemotherapeutic drug that commonly induce pathological alteration in skeletal muscles. Bone- marrow mesenchymal stem cells (BMMSCs) offer a therapeutic potential for tissue repair and regeneration. Tumour necrosis factor-alpha (TNF-α) and Interleukin-1 beta (IL-1β) display worthy biomarkers for tissue damage and repair. Objectives: The aim of the current study was to evaluate the therapeutic effect of BMMSCs on doxorubicin - induced skeletal myopathy in experimental animals, through histological studies, antioxidant activity and investigation of TNF-α, IL-1β as diagnostic parameters for muscle damage and regeneration. Methodology: 40 adult albino-rats were divided into 4 equal groups; Group-I (control group) injected with phosphate-buffered saline (PBS), Group-II: doxorubicin- induced myopathy model group; received no treatment, Group-III: doxorubicin- induced myopathy model left for spontaneous muscle recovery, and Group-IV: doxorubicin- induced myopathy treated with systemic BMMSCs. The skeletal muscle regeneration evaluated through histological and antioxidant activity studies and investigation of TNF-α, IL-1β and vascular endothelial growth factor (VEGF) levels. Results: Photomicrographic studies of the muscle fibers showed a more evident regeneration in MSCs treated groups (IV) when compared with the other groups received no treatment. A significant reduced levels of TNF-α, IL-1β, and increased both VEGF and antioxidant activity were demonstrated in group IV when compared with the other groups received no treatment. Conclusion: MSCs is a promising therapy for doxorubicin-induced skeletal myopathy. TNF-α, and IL-1β are helpful biomarkers for evaluation of SCs therapeutic efficacy. | ||||
| Keywords | ||||
| Doxorubicin; Bone Marrow Mesenchymal stem cells (BMMSCs); Tumour necrosis factor-alpha (TNF-α); albino rat; skeletal muscle | ||||
|
Statistics Article View: 61 PDF Download: 90 |
||||
